NVIDIA, King's College London, and Owkin team up to connect hospitals across the UK with federated learning, aiming to boost several fields of clinical research.
Pepticom’s technology aims to ‘vastly reduce’ risk of failure in peptide drug candidates’ discovery and development, by utilizing artificial intelligence models.
Insilico Medicine will use its next-generation AI platform to accelerate CRFH’s drug discovery and development efforts – a deal that exemplifies maturation in the market as researchers explore new ways to conduct R&D.
SEngine Precision Medicine and Atomwise recently announced a new joint venture through which the companies aim to ‘speed and streamline’ new drug discovery, says CEO.
Insilico Medicine brings in $37m to further develop its artificial intelligence work after publishing a study that demonstrates the ‘real-world potential’ of AI for drug discovery – moving the idea from theory to reality.
Clinerion is deploying Volv’s AI algorithms across its hospital network as part of a recently announced strategic collaboration that includes plans to bring an ‘enhanced value proposition’ to both companies’ expanded client base, says CEO.
Veeva Systems launches a software application aiming to reduce the time and effort of manual data entry, which will be integrated to its cloud-based suite.
'Oncology Repurposing Engine' uses artificial intelligence to identify potential drug candidates among generics and off-patent drugs that may be repurposed as cancer therapies.
Massive Bio is looking to create the world’s largest AI-enabled ‘just-in-time’ oncology site network to accelerate study recruitment – and believes that 15-20% of advanced-stage cancer patients can be enrolled in clinical trials, says CEO.
Immodulon to utilize biomarkers identified by Biodesix’ machine learning platform, aiming to accelerate the clinical development of its pancreatic treatment.
MIT has developed an ‘invisible’ device that provides several benefits over traditional patient data collection methods, including improved biomarker development and the ability to detect changes in behavior – by monitoring patients wirelessly, and through...
Recursion Pharmaceuticals plans to partner with big pharma on rare disease programs after raising $121m to build out its machine learning-enabled platform, which draws on an in-house developed dataset to support drug discovery and development.
Pharma and regulators are using machine learning to accelerate various pharmacovigilance activities – as the number of adverse event reports increases 10-12% each year, says Eli Lilly advisor.
Boehringer Ingelheim, Sanofi, Bristol-Myers Squibb, and Evotec are among the top companies with “AI-friendly” CEOs, according to a report, which suggests that these businesses will prosper driven by a more effective application of AI.
Belong.Life raises $14m as part of a Series B funding round with plans to expand its patient engagement platform, using and complementing Iqvia’s solutions “to transform patient engagement,” says Iqvia VP.
In which areas is artificial intelligence most mature? What are the challenges to widespread adoption? Tufts and DIA recently teamed up to explore these questions.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
Atomwise signs a multi-year agreement with Eli Lilly and Company through which it will apply its patented artificial intelligence technology to support Lilly’s preclinical drug discovery efforts.
Concerto HealthAI launches model to predict survival rates in lung cancer patients in an aim to garner disease insights that could improve enrollment criteria.
Artificial intelligence tools will allow the pharmaceutical companies to make predictions about diseases more effectively than before, says ImaginAB’s CEO.
The industrialized process the industry has developed over the years is not ready for the non-blockbuster environment its entering but AI can help, says Numerate executive.
Acorn AI is designed to answer questions across all phases of drug development, making data “liquid” to help pharma make quick “go/no-go” decisions, accelerate clinical trials, and demonstrate value.
China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.
GE Healthcare’s Edison platform collaborates with ACR AI-Lab to extend its AI capabilities and allows ACR members access to algorithm creation in an aim to turn research into product development.
Deep Lens closes $14m Series A financing as it continues to expand its digital pathology platform to enable patient identification at time of diagnosis, fast-tracking trial enrollment.
Bristol-Myers Squibb enters a multi-year strategic agreement with Concerto HealthAI to use machine learning to aid in protocol design for precision treatment and improved patient outcomes.
Drug development – a dynamic and evolving process – is modernizing at an unprecedented rate, says industry expert, who stresses that change must continue to fully explore the opportunities.
The clinical data analytics platform firm has raised $75m since 2015 and will continue to enhance both the platform and applications with new capabilities, says CEO.
The oncology-focused alliance brings together Worldwide’s cancer research and clinical trial operations with Deep Lens’ Viper digital pathology platform.
Datathon participants identify five repurposable drug candidates, applying AI to identify genes of interest and support target identification – a task that previously would have taken years, says industry expert.
Artificial intelligence works best in a standardized environment, say industry experts. Workflows and processes must first be aligned to successfully use the technology – is pharma ready?
Iqvia acquired UK-based Linguamatics in January 2019 as part of the company's commitment to deliver value from artificial intelligence and machine learning.
Real world evidence extraction is one area where Sanofi is using NLP text mining, a technology with applications across the R&D pipeline, from target identification to clinical trial design and pharmacovigilance.
Clinithink has secured investors to scale its technology, which leverages unstructured data to guide treatment decisions, identify clinical trial participants, and ensure proper reimbursement.
Industry 4.0 has been pitched as able to transform the way pharma manufacturing operates, Lawrence Ganti, of Innoplexus, explains how AI can be used to improve efficiency.
Awareness around the potential opportunities created by artificial intelligence has never been higher, but pharma’s biggest challenge in 2019 will be adopting and scaling the right technology to improve patient outcomes, says an industry executive.
The biopharma industry is on the precipice of making personalized medicine a reality with access to massive amounts of data, computing power, and artificial intelligence to run in silico clinical trials, says GNS Healthcare CEO.
Merck’s agreement with Cyclica will establish efficiency in its small molecule therapy development with access to Cyclica’s AI protein screening platform.
While several companies touted the potential of AI to disrupt the drug development industry in 2018, what practical applications can the industry expect next year?
The information analytics business Elsevier has launched a new cloud-based data platform, Entellect, to de-silo, contextualize, and connect drug, target, and disease data.
If the industry wants to maintain control of manufacturing operations, it has to adopt digital technologies or face being ousted by Amazon, suggested GSK’s Pharma 4.0 director.
Evotec and Immuneering are combining iPSC and AI technologies through a research collaboration to discover novel small molecules for rare hereditary metabolic diseases.
Cyclica, a Bayer G4A company, will work with Bayer to advance drug discovery. The collaboration will involve looking further into polypharmacological profiles of small molecules.
Fusion Antibodies signed an agreement with Analytics Engines to bring machine learning and AI to its humanization platform in an aim to bolster product quality and manufacturability.
